Sat Kartar

Sat Kartar Shopping Limited delivered robust financial results for the first half of FY26. Consolidated revenue reached INR 91.9 crores, marking an 18% year-on-year growth, while standalone revenue grew 17% to INR 88.35 crores. Profit after tax (PAT) margin saw a significant 100% increase, rising from 5% to 8.81%. This improvement was also reflected in EBITDA, which showed a 200-plus basis points improvement, driven by disciplined spending and operational excellence.

The company is embarking on a transformative phase by entering the Ayurveda hospital segment, aiming to become a comprehensive health and wellness ecosystem. The plan includes establishing 300 beds by the last quarter of FY27, with the first phase of 30 beds expected to be operational by Q1 2027, primarily in the NCR region. These hospitals are projected to generate approximately INR 10,000 per operational bed per day at 90% utilization, translating to a potential revenue of INR 100 crores for 300 beds, with an attractive EBITDA margin of 25-30%.

Sat Kartar has established its own manufacturing unit, which is currently at 10% utilization. The company plans to increase capsule manufacturing to at least 50% of its intake by Q1 next year, while continuing with contract manufacturing for the remainder. This unit also serves as an R&D lab for new products. Additionally, the company's AI initiatives have completed beta testing and are ready for rollout, aiming to enhance CRM intelligence, digital operations, and customer experience, making Sat Kartar one of the first Ayurveda-led companies to deploy AI at scale.

The company faced a temporary slowdown in May due to the India-Pakistan war, which resulted in a top line hit of approximately INR 6 crores and a negative impact on the bottom line. Furthermore, a glitch in India Post's software led to a 45-day delay in trade receivables, though 80% of these have already been recovered, with the rest expected within 10-15 days. Management emphasized that these challenges were temporary and the company has shown remarkable resilience and consistency, with strong momentum since June.

Management provided optimistic guidance for future profitability, targeting a PAT margin of 9-10% for the current fiscal year (FY26), 12-15% by FY27, and 18-20% by the closing of 2028. The company's repeat rate has significantly increased to 25% (from a previous 8.27% based on a different calculation methodology), and the average ticket size has grown by 5% to approximately INR 3,300. These improvements, coupled with anticipated operational efficiencies, are expected to mitigate the impact of rising customer acquisition costs in a competitive environment.

Sat Kartar acquired Plantomed, a company also in the diabetes product space, to strategically expand into the lower ticket size segment. Plantomed's products have a ticket size of INR 1,300, complementing Sat Kartar's existing diabetes products which are in the INR 2,500-2,600 range. The acquisition is performing well, currently generating INR 60 lakhs in monthly turnover and is projected to exceed INR 1 crore monthly within the next two months, demonstrating exponential growth.